-
公开(公告)号:PT1025100E
公开(公告)日:2002-07-31
申请号:PT98951491
申请日:1998-10-05
Applicant: BASF AG
Inventor: STEINER GERD , TESCHENDORF HANS-JUERGEN , EMLING FRANZ , WICKE KARSTEN , LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , BACH ALFRED , GARCIA-LADONA XAVIER
IPC: A61K31/519 , A61P1/00 , A61P1/14 , A61P3/04 , A61P5/00 , A61P9/12 , A61P15/00 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D471/00 , C07D471/04
Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.
-
122.
公开(公告)号:AU748613B2
公开(公告)日:2002-06-06
申请号:AU1149799
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , BACH ALFRED , EMLING FRANZ , GARCIA-LADONA XAVIER , TESCHENDORF HANS-JURGEN , WICKE KARSTEN
IPC: A61K31/428 , A61P25/24 , A61P43/00 , C07D275/06 , C07D417/04 , C07D417/06 , C07D417/12 , C07D417/14 , A61K31/425
Abstract: where the substituents have the meanings indicated in the description, their preparation and use as serotonin antagonists.
-
公开(公告)号:DK1025100T3
公开(公告)日:2002-05-06
申请号:DK98951491
申请日:1998-10-05
Applicant: BASF AG
Inventor: LUBISCH WILFRIED , DULLWEBER UTA , STARCK DOROTHEA , STEINER GERD , BACH ALFRED , EMLING FRANZ , GARCIA-LADONA XAVIER , TESCHENDORF HANS-JUERGEN , WICKE KARSTEN
IPC: A61K31/519 , A61P1/00 , A61P1/14 , A61P3/04 , A61P5/00 , A61P9/12 , A61P15/00 , A61P25/00 , A61P25/22 , A61P25/24 , A61P25/28 , A61P43/00 , C07D471/00 , C07D471/04
Abstract: 3-substituted tetrahydropyridopyrimidinone derivatives of the formula (I) wherein the radicals have the meanings given in the Description, to a method for producing said derivatives and, to their use for producing active ingredients for drugs.
-
公开(公告)号:MXPA01006967A
公开(公告)日:2002-04-10
申请号:MXPA01006967
申请日:1999-12-24
Applicant: BASF AG
Inventor: STARCK DOROTHEA
IPC: C07D495/04 , A61K31/505 , A61K31/519 , A61P9/10 , C07D495/14 , A61K31/495 , A61K31/55
Abstract: Se describe el uso de derivados de pirimidina de la formula I (ver formula) en donde los sustituyentes son de conformidad con lo definido en la descripcion, y sus sales fisiologicamente toleradas para la produccion de farmacos para la profilaxis y tratamiento isquemia cerebral y apoplejias.
-
公开(公告)号:SK9862001A3
公开(公告)日:2002-04-04
申请号:SK9862001
申请日:2000-01-12
Applicant: BASF AG
Inventor: STARCK DOROTHEA , TREIBER HANS-JORG , UNGER LILIANE , NEUMANN-SCHULTZ BARBARA , BLUMBACH KAI , SCHOBEL DIETMAR
IPC: A61K31/41 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/436 , A61K31/4439 , C07D249/14 , A61K31/4725 , A61K31/473 , A61K31/496 , A61K31/497 , A61K31/5377 , A61K31/55 , A61P3/04 , A61P9/00 , A61P9/10 , A61P13/12 , A61P15/10 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/28 , A61P25/30 , A61P25/32 , A61P25/34 , A61P25/36 , A61P43/00 , C07D249/12 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D491/04 , C07D491/052 , A61P25/24 , C07D413/12
Abstract: Triazole compounds of the following formulawhere R1, R2, A and B have the meanings given in the description are described. The compounds according to the invention possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to the influence of dopamine D3 ligands.
-
公开(公告)号:BG105689A
公开(公告)日:2002-02-28
申请号:BG10568901
申请日:2001-07-10
Applicant: BASF AG
Inventor: STEINER GERD , SCHNELLHAAS KURT , LUBISCH WILFRIED , HOLZENKAMP UTA , STARCK DOROTHEA , KNOPP MONIKA , SZABO LASZLO , EMLING FRANZ , GARCIA-LADONA FRANCISCO J , HOFMANN HANS-PETER , UNGER LILIANE
IPC: C07D495/04 , A61K31/505 , A61K31/519 , A61P9/10 , C07D495/14 , A61K31/495 , A61K31/55
Abstract: The invention relates to the utilization of pyrimidine derivatives of formula wherein the substituents have the meaning cited in the description, and to the utilization of the physiologically compatible salts thereof for producing medicaments used for preventing and treating cerebral ischaemia and strokes. 1 claim
-
公开(公告)号:NO20015413L
公开(公告)日:2001-11-15
申请号:NO20015413
申请日:2001-11-06
Applicant: BASF AG
Inventor: MUEHLBAUER BERND , GROSS GERHARD , STARCK DOROTHEA , TREIBER HANS-JOERG
IPC: C07D241/04 , A61K31/00 , A61K31/472 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5513 , A61K45/00 , A61P1/00 , A61P13/12 , C07D401/12 , C07D403/12 , A61K31/4196
Abstract: The invention relates to the use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders.
-
公开(公告)号:NO20015413A
公开(公告)日:2001-11-15
申请号:NO20015413
申请日:2001-11-06
Applicant: BASF AG
Inventor: MUEHLBAUER BERND , GROSS GERHARD , STARCK DOROTHEA , TREIBER HANS-JOERG
IPC: C07D241/04 , A61K31/00 , A61K31/472 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5513 , A61K45/00 , A61P1/00 , A61P13/12 , C07D401/12 , C07D403/12 , A61K31/4196
CPC classification number: A61K31/517 , A61K31/00 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/506
-
公开(公告)号:NO20015413D0
公开(公告)日:2001-11-06
申请号:NO20015413
申请日:2001-11-06
Applicant: BASF AG
Inventor: MUEHLBAUER BERND , GROSS GERHARD , STARCK DOROTHEA , TREIBER HANS-JOERG
IPC: C07D241/04 , A61K31/00 , A61K31/472 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5513 , A61K45/00 , A61P1/00 , A61P13/12 , C07D401/12 , C07D403/12 , A61P
Abstract: The invention relates to the use of dopamine D3 receptor ligands for the production of drugs for treating renal function disorders.
-
公开(公告)号:BR0007504A
公开(公告)日:2001-10-02
申请号:BR0007504
申请日:2000-01-12
Applicant: BASF AG
Inventor: STARCK DOROTHEA , TREIBER HANS JORG , UNGER LILIANE , NEUMANN-SCHULTZ BARBARA , BLUMBACH KAI , BEL DIETMAR SCH
IPC: C07D249/14 , A61K31/41 , A61K31/4196 , A61K31/422 , A61K31/4245 , A61K31/427 , A61K31/436 , A61K31/4439 , A61K31/4725 , A61K31/473 , A61K31/496 , A61K31/497 , A61K31/5377 , A61K31/55 , A61P3/04 , A61P9/00 , A61P9/10 , A61P13/12 , A61P15/10 , A61P25/00 , A61P25/08 , A61P25/14 , A61P25/16 , A61P25/18 , A61P25/20 , A61P25/22 , A61P25/28 , A61P25/30 , A61P25/32 , A61P25/34 , A61P25/36 , A61P43/00 , C07D249/12 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/06 , C07D403/12 , C07D403/14 , C07D405/06 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/12 , C07D417/14 , C07D491/04 , C07D491/052 , A61P25/24 , C07D413/12
Abstract: Triazole compounds of the following formulawhere R1, R2, A and B have the meanings given in the description are described. The compounds according to the invention possess a high affinity for the dopamine D3 receptor and can therefore be used for treating diseases which respond to the influence of dopamine D3 ligands.
-
-
-
-
-
-
-
-
-